UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organiza ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being ...

Corporate Presentation November 2022 :INO Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Jacqueline Shea - President and CEO Conference Call Participants Brooke Katsof - H.C. Wainwright Brooke Katsof Good morning, everyone and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference from September 12 to the 14, 2022. My name is Brooke Katsof and I'm an H.C. Wainwright analyst. While we are hybrid this year, we're c ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Thomas Hong - IR Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer David Liebowitz - SVP, Clinical Development Jeffrey Skolnik - SVP, Clinical Development Peter Kies - CFO Conference Call Participants Alexandria Hammond - Bank of America Merrill Lynch Gregory Renza - RBC Capital Markets Jiale Song - Jefferies Eka Gigauri - Oppenheimer Raghuram Selvaraju - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q COMMISSION FILE NO. 001-14888 https://files.reportify.cc/media/p INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 660 W. GERMANTOWN PIKE, SUITE 110 PLYMOUTH MEETING, PA 19462 (Address of principal executive offices) REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (267) 4 ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Jefferies 2022 Global Healthcare Conference June 8, 2022 1:00 PM ET Company Participants Jacqui Shea - CEO Jeffrey Skolnik - CMO Conference Call Participants Roger Song - Jefferies Roger Song Good afternoon, everyone. Welcome to Jefferies Global Healthcare Conference day one afternoon. My name is Roger Song, one of the senior analysts on the biotech research team in the US. Our next presenting company from -- is Inovio and the presenter is the CEO, Jacqui and CMO, J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of ...

Company Focus - INOVIO is dedicated to developing DNA medicines and vaccines for infectious diseases, cancer, and HPV-related conditions [5] - The company's technology combines precisely designed plasmids with proprietary smart devices for delivery [5] - INOVIO's DNA medicines can be designed quickly through optimized SynCon® technology [9] COVID-19 and Infectious Diseases - INOVIO is jointly conducting a global Phase 3 trial for INO-4800 with Advaccine, focusing on countries underserved by vaccines [10] - The WHO selected INO-4800 for its global Phase 3 Solidarity Trial Vaccines, enrolling 40,000 participants [11] - Approximately 1 billion doses of Chinese vaccines have been administered to 110 countries, creating a potential market for heterologous boosters [15] HPV Program - In the US, approximately 80 million Americans are currently infected with HPV, with 14 million new infections annually [17] - VGX-3100 Phase 3 REVEAL1 trial achieved statistical significance for primary objective in all evaluable participants: 23.7% in the treatment group vs 11.3% in the placebo group [21] - INO-3107 has completed enrollment of 32 participants in a Phase 1/2 clinical trial for Recurrent Respiratory Papillomatosis (RRP) [25, 26] Immuno-Oncology - In the GBM study, 84.4% of MGMT Unmethylated (Cohort A) and 85.0% of MGMT Methylated (Cohort B) were alive at 12 months [32]